ライフサイエンスコーパス: DVT

1 DVT affects most frequently the lower limbs and hence DV

2 DVT is a thromboinflammatory disorder developing largely

3 ntly higher FDG uptake than organized day 14 DVT (P=0.03).

4 hil depletion decreased FDG signals in day 2 DVT in comparison with controls (P=0.03).

5 9.7%, pulmonary embolus (PE) alone in 25.4%, DVT plus PE in 13.6%, arterial TEE alone in 8.3%, or DVT

6 ith a diagnosis of VTE that comprised 87,605 DVTs and 65,913 PEs (with and without DVT).

7 VT [3/184 (1.6%) vs 5/192 (2.6%); P = 0.72], DVT at 30 days (1.6% vs 3.6%; P = 0.34) or bleeding comp

8 or postthrombotic syndrome (PTS) after acute DVT.

9 diologists blinded for the presence of acute DVT and a third in case of disagreement.

10 c therapy for the initial treatment of acute DVT.

11 ary embolism was induced 30 min or 2 d after DVT by intrajugular injection of a preformed blood clot

12 do not support routine wearing of ECS after DVT.

13 and PE but were 3- to 5-fold increased after DVT and 6- to 11-fold increased after PE when VTE was co

14 Although 30-day mortality after DVT remained fairly constant over the last 3 decades, it

15 tion of lung emboli and venous thrombi after DVT-PE, revealing significant differences in uptake betw

16 atelets to the inferior vena cava wall after DVT induction were reduced in MC-deficient mice.

17 c deficiency in CLEC-2 are protected against DVT.

18 tion of NETs each confers protection against DVT amplification.

19 OR, 0.13 [CI, 0.03 to 0.54]; ARR, 0.7%), and DVT (7 trials; RR, 0.37 [CI, 0.21 to 0.64]; ARR, 12.1%)

20 ximately 3 of every 4 pulmonary embolism and DVT events occur outside the hospital setting, patients

21 findings suggest that pulmonary embolism and DVT may not always have the same etiology, and encourage

22 Sex, DVT triggering event, and DVT resolution predicted LE-PTS in our cohort.

23 ions include imprecise definitions of PE and DVT.

24 1,119 with any PE, and 272 with both PE and DVT.

25 the risk for venous thromboembolism, PE, and DVT while increasing the risk for minor bleeding in pati

26 ents with central venous catheter-associated DVT, calf DVT, and unsuspected VTE.

27 he occurrence of symptomatic or asymptomatic DVT in the popliteal or femoral veins.

28 ET/computed tomography (CT) was performed at DVT time points of day 2, 4, 7, 14, or 2+16 (same-site r

29 Because DVT formation and resolution are associated with a prepo

30 ion was performed in a subset of mice before DVT formation and FDG-PET/CT.

31 scores >1; there was an interaction between DVT triggering event and sex.

32 RRs remained 25% to 40% increased after both DVT and PE but were 3- to 5-fold increased after DVT and

33 nticoagulation and those with a chronic calf DVT, a contraindication to anticoagulation, prior venous

34 central venous catheter-associated DVT, calf DVT, and unsuspected VTE.

35 dentified 697 patients with an isolated calf DVT and excluded 313 of these.

36 trasonographic detection of an isolated calf DVT from January 1, 2010, to December 31, 2013, at the V

37 d sonographically proven acute isolated calf DVT.

38 0 days of the diagnosis of the isolated calf DVT.

39 oximal DVT or PE are low after isolated calf DVT.

40 gnosis of a PE suspected at the time of calf DVT diagnosis were excluded.

41 oppler sonography for the evaluation of calf DVT may be limited by patient characteristics such as ob

42 The calf DVT involved an axial vein (anterior tibial, posterior t

43 signal decrease in both murine and clinical DVT.

44 The crude cumulated DVT rate for all the trials was 5.9% for GCS and 2.8% fo

45 eoperative IVC filter insertion demonstrated DVT rates of 0% to 20.8% and PE rates ranging from 0% to

46 Patients with both proximal and distal DVT had a higher recurrence rate than proximal (17/48 35

47 hole-leg CUS may exclude proximal and distal DVT in a single evaluation.

48 ts (0.7%), including 11 patients with distal DVT (32.4%); 7 patients with proximal DVT (20.6%); 7 pat

49 ently been shown to boost coagulation during DVT, the underlying molecular mechanisms are not fully r

50 atients with cancer enrolled in the EINSTEIN-DVT and EINSTEIN-PE randomised controlled trials.

51 no cancer who were enrolled in the EINSTEIN-DVT and EINSTEIN-PE trials.

52 patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolism (EINSTEIN-PE) were randomly a

53 deep vein thrombosis and pulmonary embolism (DVT-PE).

54 aged 18 to 70 years following the first-ever DVT.

55 MCs exacerbate DVT likely through endothelial activation and Weibel-Pal

56 cally the initial test to confirm or exclude DVT.

57 ical study, 38 patients with lower extremity DVT or controls undergoing FDG-PET were analyzed.

58 The FDG DVT signal in patients also exhibited a time-dependent d

59 d and validated for the diagnosis of a first DVT, no such well-defined strategies exist in the case o

60 In patients with cancer with a first DVT, treated for 6 months with LMWH, absence of RVT iden

61 30-year MRR was 1.55 (95% CI, 1.53-1.57) for DVT and 2.77 (95% CI, 2.74-2.81) for PE.

62 30-day MRR was 5.38 (95% CI, 5.00-5.80) for DVT and 80.87 (95% CI, 76.02-86.02) for PE.

63 target for an anti-inflammatory approach for DVT prophylaxis.

64 orting on the use of compression devices for DVT prevention.

65 CDT should be employed for DVT patients who have severe clinical manifestations suc

66 Compression devices are often employed for DVT prophylaxis in these patients.

67 and are the only identified risk factor for DVT that can be ameliorated by physicians.

68 tes for several established risk factors for DVT and pulmonary embolism separately.

69 apy as the only independent risk factors for DVT formation.

70 E in TPKA studies but less heterogeneity for DVT and pulmonary embolism in TPKA studies and for VTE,

71 was consistently 5- to 6-fold increased for DVT, whereas it improved for PE from 138 (95% CI, 125-15

72 rval [CI]: 0.33 to 0.75); increased risk for DVT (OR: 1.70; 95% CI: 1.17 to 2.48); nonsignificantly l

73 ositive test result on the basis of risk for DVT might improve the tradeoff between sensitivity and s

74 oxaparin prophylaxis in patients at risk for DVT should be optimized.

75 risk of subsequent PE, increase the risk for DVT, and have no significant effect on overall mortality

76 For men on endocrine therapy, risks for DVT (SIR 2.48, 95% CI 2.25-2.73) and pulmonary embolism

77 othelium provide the initiating stimulus for DVT development.

78 n and validate MCs as a potential target for DVT prevention.

79 cient for MCs were completely protected from DVT.

80 In general, DVT and PE patients require 3 months of treatment with a

81 Forty-six patients had DVT but no PE.

82 estigated how many of these four vessels had DVT and compared them with respect to the pulsatility in

83 ts most frequently the lower limbs and hence DVT of the leg will be the focus of this article.

84 Patients with acute iliofemoral DVT represent a subgroup at particularly high risk of de

85 or patients with extensive acute iliofemoral DVT, low expected bleeding risk, and good functional sta

86 for selected patients with acute iliofemoral DVT.

87 )Cu-FBP8 PET is a feasible approach to image DVT-PE and that radiogenic adverse health effects should

88 There was no change in DVT rates before and after CLOTS-1 (0.8% vs 1.0%).

89 The difference in DVT outcome only reached statistic significance in 3, al

90 There was no difference in DVT resolution (P = .41).

91 ality and are associated with an increase in DVT events.

92 to determine the role of mast cells (MCs) in DVT initiation and validate MCs as a potential target fo

93 Platelets play a role in DVT, but the impact of specific platelet receptors remai

94 d therefore that CLEC-2 might play a role in DVT.

95 We established a stasis-induced DVT model in murine jugular veins and also a novel model

96 Location and extent of the initial DVT, recurrence, pulmonary embolism, cause of mortality,

97 ients with symptomatic recurrent ipsilateral DVT (incompressibility of a different proximal venous se

98 DTI demonstrated acute recurrent ipsilateral DVT in 37 of 39 patients and was normal in all 42 patien

99 In conclusion, LR LE-DVT had more benign outcomes than Non-LR DVT.

100 We investigated the outcomes of LE-DVT in children.

101 non-neonates, respectively), of recurrent LE-DVT (P = .001; 10.7% and 2.0% in Non-LR and LRnon-neonat

102 ric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic syndrome (PTS) and other

103 and odds ratios (ORs) (and 95% CIs) of left DVT per 1% increase in percentage compression were calcu

104 ing compression was not associated with left DVT (adjusted ORs, 1.00, 0.99, 1.02) but above 70%, LCIV

105 LCIV compression may be associated with left DVT (adjusted ORs, 3.03, 0.91, 10.15).

106 ht DVT were more likely than those with left DVT to have a history of pulmonary embolism.

107 70% compression may be associated with left DVT.

108 one-fourth to one-half of all diagnosed leg DVTs.

109 3, all of which showed IPC to have the lower DVT rate.

110 DVT, LR DVT in neonates (LRneonates), and LR DVT in non-neonates (LRnon-neonates).

111 compared: non-line-related (Non-LR) DVT, LR DVT in neonates (LRneonates), and LR DVT in non-neonates

112 LE-DVT had more benign outcomes than Non-LR DVT.

113 ups were compared: non-line-related (Non-LR) DVT, LR DVT in neonates (LRneonates), and LR DVT in non-

114 ut are not sufficient to prevent PTS in many DVT patients.

115 METHODS AND In a mouse model, DVT was induced by partial ligation (stenosis) of the in

116 Here, using a murine DVT model of inferior vena cava (IVC) stenosis, we demon

117 il-dependent thrombus inflammation in murine DVT, and demonstrates a time-dependent signal decrease i

118 tion is set in motion leading to obstructive DVT formation.

119 s and myeloid leukocytes fostering occlusive DVT formation.

120 of postthrombotic syndrome in 25% to 60% of DVT patients.

121 as not the primary reason for the absence of DVT in VWF(-/-) mice.

122 ible for the initiation and amplification of DVT and for inducing its unique clinical features.

123 d for outpatient management of most cases of DVT in the acute phase.

124 raluminal fibrin formation characteristic of DVT.

125 The consequences of DVT include the development of postthrombotic syndrome i

126 type 9 (PCSK9) deficiency on development of DVT in mice.

127 ts with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for

128 tive patients with an acute first episode of DVT.

129 ent NTDB cohort, there were 9398 episodes of DVT (1.06%) and 3738 of PE (0.42%).

130 as associated with an increased incidence of DVT (OR = 1.83; 95% CI, 1.15-2.93, P-value = 0.01).

131 mportant triggering factor, the mechanism of DVT initiation remains elusive.

132 Thus, we propose a novel mechanism of DVT, whereby CLEC-2 and upregulation of podoplanin expre

133 Cellular mechanisms of DVT initiation remain poorly understood.

134 Mechanisms of DVT remain incompletely understood.

135 We describe a novel mouse model of DVT which reproduces a frequent trigger and resembles th

136 ls were created to examine the predictors of DVT and PE and PE-related mortality.

137 gical features, and clinical presentation of DVT in humans.

138 nsidered potential targets for prevention of DVT in humans.

139 TE rate was 0.96% (n = 13,809); the rates of DVT and PE were 0.71% (n = 10,198) and 0.33% (n = 4772),

140 trategies exist in the case of recurrence of DVT.

141 Recurrences of DVT were associated with faster formation (-9% lag phase

142 remodeling associated with the resolution of DVT.

143 ween plasma fibrinogen quintiles and risk of DVT alone (P-trend = 0.4).

144 rinogen is associated with increased risk of DVT alone, with any PE, and with PE in combination with

145 No increased risk of DVT was identified, nor any TEE reported in rhC1INH trea

146 There is an increased risk of DVT with surgery, particularly in patients who are not e

147 mpression stockings (GCS) reduce the risk of DVT.

148 leukocyte recruitment in the early stages of DVT was dramatically higher in wild-type than in VWF(-/-

149 ory approaches to prophylaxis and therapy of DVT.

150 dies are needed to further assess the use of DVT imaging as an appropriate adjunctive diagnostic tool

151 lmonary embolism, but little or no effect on DVT.

152 perative VTE, bleeding complications, and OP-DVT.

153 Eighteen patients (4.2%) had OP-DVT and were excluded.

154 The risk of OP-DVT is higher than that of perioperative DVT after color

155 r colorectal surgery and the incidence of OP-DVT remains unclear.

156 Those without OP-DVT were randomized to preoperative or postoperative CTP

157 PE in 13.6%, arterial TEE alone in 8.3%, or DVT plus arterial TEE in 3.0%.

158 ubjects with suspected pulmonary embolism or DVT and account for one-fourth to one-half of all diagno

159 se may not be causally associated with PE or DVT.

160 iants were not associated with risk of PE or DVT.

161 ned as D-dimer testing for all participants (DVT excluded at D-dimer levels <0.5 microg/mL).

162 OP-DVT is higher than that of perioperative DVT after colorectal surgery and preoperative screening

163 tive CTP with respect to early postoperative DVT [3/184 (1.6%) vs 5/192 (2.6%); P = 0.72], DVT at 30

164 lade body secretagogue from MCs, potentiated DVT in wild-type mice, and histamine restored thrombosis

165 all D-dimer assays or patients with previous DVT, study personnel were not blinded, and the trial was

166 e recurrent DVT at day 2 overlying a primary DVT at day 16).

167 nt proximal venous segment than at the prior DVT) and 42 asymptomatic patients with at least 6-month-

168 The sequence of events that promote DVT remains obscure, largely as a result of the lack of

169 Proximal DVT alone, higher C-reactive protein, D-dimer, peak thro

170 Proximal DVT occurred in 7 controls (5.0%) and 4 anticoagulation

171 Proximal DVT or PE within 180 days of the diagnosis of the isolat

172 of pharmacomechanical CDT for acute proximal DVT.

173 [CI, 0.16 to 0.81]; ARR, 1.5%), and proximal DVT (6 trials; RR, 0.29 [CI, 0.16 to 0.52]; ARR, 7.1%).

174 utcomes for patients with extensive proximal DVT.

175 years to prevent PTS after a first proximal DVT in centres in Canada and the USA.

176 S did not prevent PTS after a first proximal DVT, hence our findings do not support routine wearing o

177 ssociated with a decreased risk for proximal DVT or PE at 180 days (odds ratio [OR], 0.34; 95% CI, 0.

178 Rates of proximal DVT or PE are low after isolated calf DVT.

179 resenting with a first symptomatic, proximal DVT were potentially eligible to participate.

180 definitely after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the in

181 y balanced after a first unprovoked proximal DVT or pulmonary embolism (PE).

182 distal DVT (32.4%); 7 patients with proximal DVT (20.6%); 7 patients with nonfatal pulmonary emboli (

183 for outpatients with low or moderate C-PTP (DVT excluded at D-dimer levels <1.0 microg/mL [low C-PTP

184 Recurrent DVT demonstrated significantly higher FDG uptake than or

185 Recurrent DVT was observed in 77 patients (25%; 6.6%/year) during

186 composite of centrally adjudicated recurrent DVT, fatal or nonfatal pulmonary embolism, and incidenta

187 ng strategy to accurately diagnose recurrent DVT.

188 r distinguishing acute ipsilateral recurrent DVT from 6-month-old chronic residual thrombi in the leg

189 6 min) were at the highest risk of recurrent DVT (odds ratio, 15.8; 95% confidence interval, 7.5-33.5

190 vidence regarding the treatment of recurrent DVT is sparse, in particular when it comes to deciding o

191 for the diagnosis and treatment of recurrent DVT will be put forward.

192 Two typical cases of recurrent DVT, one with an unprovoked DVT and one with DVT during

193 d thereby improve the diagnosis of recurrent DVT.

194 term natural history and impact of recurrent DVT.

195 ltered clot properties may predict recurrent DVT after anticoagulation withdrawal.

196 ced Ks and prolonged CLT predicted recurrent DVT.

197 ay 2, 4, 7, 14, or 2+16 (same-site recurrent DVT at day 2 overlying a primary DVT at day 16).

198 effectiveness of thigh-length GCS to reduce DVT after stroke.

199 prevention of MC degranulation also reduced DVT.

200 rformed (independent variable, left vs right DVT; dependent variable, iliac vein compression).

201 Patients with right DVT were more likely than those with left DVT to have a

202 Sex, DVT triggering event, and DVT resolution predicted LE-PT

203 pression were not associated with left-sided DVT up to 70%; however, greater than 70% compression may

204 Stasis DVT demonstrated that the highest FDG signal occurred at

205 igation of the jugular vein to induce stasis DVT.

206 s and also a novel model of recurrent stasis DVT in mice.

207 neutrophils are indispensable for subsequent DVT propagation by binding factor XII (FXII) and by supp

208 0.69-1.27) and men who were on surveillance (DVT: 1.27, 1.08-1.47; pulmonary embolism: 1.57, 1.38-1.7

209 when diagnosing a first episode of suspected DVT.

210 ve cohort studies of patients with suspected DVT and a negative whole-leg CUS result who did not rece

211 [CI, 0.31 to 0.75]; ARR, 5.8%), symptomatic DVT (4 trials; OR, 0.36 [CI, 0.16 to 0.81]; ARR, 1.5%),

212 The pooled rates of symptomatic DVT were 0.63% (95% CI, 0.47%-0.78%) for knee arthroplas

213 = 3) conferred a much higher risk of PE than DVT.

214 is male, the index event was PE rather than DVT, and/or d-dimer testing is positive 1 month after st

215 ultivariable logistic regression showed that DVT pathogenesis and imaging-determined degree of thromb

216 Multivariable analysis showed that DVT resolution, triggering event, and sex predicted Modi

217 The DVT rate did not differ between trauma and general surge

218 The DVTs occurred in 23.5% of patients who missed at least 1

219 pulmonary embolism, venous thromboembolism (DVT and/or pulmonary embolism), and myocardial infarctio

220 casian man arrived with deep vein thrombosis DVT, pain, oedema and rubor of right lower limb and drug

221 TEEs included deep vein thrombosis (DVT) alone in 49.7%, pulmonary embolus (PE) alone in 25.

222 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonary embolism have high m

223 Deep vein thrombosis (DVT) and its complication, pulmonary embolism, are frequ

224 ients with cancer with deep vein thrombosis (DVT) and low-risk pulmonary embolism.

225 lism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common, potential

226 lism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant sourc

227 her risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

228 Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as ve

229 Deep vein thrombosis (DVT) and pulmonary embolism are common after stroke.

230 assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule were performed, and le

231 of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical problem.

232 Deep vein thrombosis (DVT) is a major cause of cardiovascular death.

233 ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge because differentiati

234 Deep-vein thrombosis (DVT) is regarded a chronic disease as it often recurs.

235 Deep vein thrombosis (DVT) isolated to the calf veins (distal to the popliteal

236 s with cancer who have deep vein thrombosis (DVT) of the lower limbs.

237 ly documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy great

238 CS are recommended for deep vein thrombosis (DVT) prophylaxis in surgical patients.

239 compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthopedic and neurological

240 ium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates remain high in the traum

241 learly higher risk for deep-vein thrombosis (DVT) than for pulmonary embolism.

242 Deep vein thrombosis (DVT) with its major complication, pulmonary embolism, is

243 pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect relationship has not been

244 pected lower extremity deep vein thrombosis (DVT), compression ultrasound (CUS) is typically the init

245 isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and is usually treate

246 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and VTE within 30 days of

247 can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive patients aged 18 to 70

248 fter acute symptomatic deep vein thrombosis (DVT).

249 (PTS) in patients with deep vein thrombosis (DVT).

250 and the development of deep vein thrombosis (DVT).

251 y approach to isolated calf vein thrombosis (DVT).

252 tality, and subsequent deep vein thrombosis (DVT).

253 nitiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was not known or suspected a

254 0.8%), asymptomatic deep venous thrombosis (DVT) (4 trials; relative risk [RR], 0.48 [CI, 0.31 to 0.

255 associated with both deep venous thrombosis (DVT) and its complication, pulmonary embolism (PE), and

256 ks for patients with deep venous thrombosis (DVT) and pulmonary embolism (PE) were markedly higher th

257 been associated with deep venous thrombosis (DVT) in the general population are risk factors for SLE

258 on the incidence of deep venous thrombosis (DVT) is controversial.

259 Deep venous thrombosis (DVT) is one of the most common cardiovascular diseases,

260 Deep venous thrombosis (DVT) remains a common and serious cardiovascular problem

261 d the association of deep venous thrombosis (DVT) with the presence of an IVC filter, accounting for

262 ence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and arterial embolism were cal

263 , pneumonia, sepsis, deep venous thrombosis (DVT), pulmonary embolism, venous thromboembolism (DVT an

264 some complication of deep venous thrombosis (DVT).

265 cific for diagnosing deep venous thrombosis (DVT).

266 erent from those for deep venous thrombosis (DVT).

267 sion stockings (GCS) for deep vein thrombus (DVT) prophylaxis in acute stroke patients before and aft

268 ients were analyzed in 3 groups according to DVT pathogenesis and neonatal status: primary (G1), seco

269 s via glycoprotein Ibalpha and contribute to DVT progression by promoting leukocyte recruitment and s

270 ase, we found both pulmonary embolism due to DVT and paradoxical embolism due to existing patent fora

271 een for men who received curative treatment (DVT: 1.73, 1.47-2.01; pulmonary embolism: 2.03, 1.79-2.3

272 rt of children with objectively confirmed UE-DVT.

273 c UE-PTS frequency and severity depend on UE-DVT pathogenesis (primary/secondary) and, within the sec

274 ric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic syndrome (PTS) is still la

275 he pelvis prior to a diagnosis of unilateral DVT.

276 Unprovoked DVT and age >65 years were associated with higher recurr

277 ses of recurrent DVT, one with an unprovoked DVT and one with DVT during anticoagulation, will be pre

278 igher rate of recurrence included unprovoked DVT and age >65.

279 monary embolism in TPKA studies and for VTE, DVT, and pulmonary embolism in TPHA studies.

280 analysts, and pooled incidence rates of VTE, DVT, and pulmonary embolism were estimated using random-

281 red separately to hospitalizations with VTE, DVT, or PE that had no corresponding comorbidities, cong

282 ately 41,944 in-hospital deaths (20,212 with DVT and 21,732 with PE) occurred among 770,137 hospitali

283 d male sex (75% vs 56%) were associated with DVT formation (P < .05 for all).

284 nd age 50 years or older are associated with DVT formation among trauma and general surgery patients.

285 d in vitamin K reduction and associated with DVT, correlate with SLE development in Asian subjects.

286 ith increased risk of PE in combination with DVT (P-trend < 0.0001): multivariable adjusted odds rati

287 ith increased risk of PE in combination with DVT but not with DVT alone.

288 with any PE, and with PE in combination with DVT.

289 opulation, of whom 1,679 were diagnosed with DVT alone, 1,119 with any PE, and 272 with both PE and D

290 he proportion of patients not diagnosed with DVT during initial testing who had symptomatic venous th

291 ons with VTE and among hospitalizations with DVT or PE.

292 k of PE in combination with DVT but not with DVT alone.

293 DVT, one with an unprovoked DVT and one with DVT during anticoagulation, will be presented.

294 isk factors, and outcomes from patients with DVT and PE compiled in the recent years (2007-2009) in t

295 Patients with DVT due to surgery or trauma had a lower recurrence (P <

296 to accelerate this process in patients with DVT.

297 d 1.9 (95% CI, 1.0-3.6) for PE in those with DVT (P-trend = 0.003).

298 spitalizations with VTE and among those with DVT or PE.

299 87,605 DVTs and 65,913 PEs (with and without DVT).

300 deep vein thrombosis (DVT) prophylaxis, yet DVT rates remain high in the trauma and general surgery